Proactiveinvestors recommends
Additional Information
Market: TSX
Sector: Medical
EPIC: IM
Latest Price: 2.90  (-3.01% Descending)
52-week High: 8.35
52-week Low: 2.33
Market Cap: 130.18M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Imris
www.imris.com

IMRIS provides integrated surgical and interventional suites that incorporate magnetic resonance, fluoroscopy and computed tomography to deliver on demand imaging during procedures. The Company's systems serve the neurosurgical, cardiovascular and neurovascular markets.

Full Imris profile here
Pdf

Imris acquires neurosurgical robot developer NeuroArm Surgical

4th Feb 2010, 1:57 pm
Imris acquires neurosurgical robot developer NeuroArm Surgical

IMRIS (TSX: IM) is acquiring NeuroArm Surgical Limited, a privately held company that has developed a magnetic resonance-compatible neurosurgical robot.


The robot is designed to perform microsurgery and biopsy-stereotaxy applications on the brain with “unprecedented precision”.  “To management's knowledge, it is the only surgical robot in the world that a surgeon can use together with a magnetic resonance (MR) scanner in the operating room,” Imris stated this morning.


IMRIS has also separately entered into a memorandum of understanding (MOU) with MacDonald Dettwiler and Associates to create the next generation of the technology, and will also enter into a collaboration agreement with the University of Calgary to “leverage its clinical setting and data”.  The first generation of the robot was developed at the University of Calgary and is currently used to perform neurosurgical procedures within one of Imris’ neuro suites at Calgary’s Foothills Hospital.


"This acquisition will deepen IMRIS's offering of image guided therapy solutions, by bringing surgical robotics together with MR imaging," said David Graves, IMRIS Chief Executive Officer. "This technology offers the potential to increase neurosurgical precision and contribute to less invasive procedures."


IMRIS is issuing 1.6 million shares as consideration for the acquisition.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.